The oral MDM2/p53 antagonist BI 907828 elicited preliminary antitumor activity and had a manageable safety profile in patients with MDM2-amplified dedifferentiated liposarcoma.
LANDMARK INTERNATIONAL COLLABORATION CREATES A FOUNDATION FOR DRUG DEVELOPMENT IN YOUNG ADULT CANCER CALLED CCS, OPENING THE DOOR TO NEW POTENTIAL THERAPY